US Pharma MarketingPost-Hoc: The world
Eli Lilly has stopped disclosing its early-stage pipeline and most deal values as it grows larger. An analysis of why the drugmaker Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
Eli Lilly is getting more opaque as it gets bigger.
Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects vanished from the company’s earnings presentation and were pulled from ...
Source: Endpoints News